(19)
(11) EP 4 408 419 A1

(12)

(43) Date of publication:
07.08.2024 Bulletin 2024/32

(21) Application number: 22790054.5

(22) Date of filing: 30.09.2022
(51) International Patent Classification (IPC): 
A61K 31/4166(2006.01)
A61K 47/14(2017.01)
A61K 47/44(2017.01)
A61K 9/107(2006.01)
A61K 47/22(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0095; A61K 47/44; A61K 47/22; A61K 31/4166; A61K 9/107; A61K 47/14; A61P 35/00
(86) International application number:
PCT/IB2022/059345
(87) International publication number:
WO 2023/053084 (06.04.2023 Gazette 2023/14)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 01.10.2021 IN 202111044703

(71) Applicant: Ferring B.V.
2132 JX Hoofddorp (NL)

(72) Inventors:
  • PADHI, BijayKumar
    Hyderabad 500 501 (IN)
  • BIRADAR, Shailesh Vishwanath
    Hyderabad 500 501 (IN)
  • SONGA, Ambedkar Sunil
    Hyderabad 500 501 (IN)

(74) Representative: Bates, Philip Ian 
Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street
London E1 8QS
London E1 8QS (GB)

   


(54) ORAL LIQUID ENZALUTAMIDE COMPOSITIONS